More recently, RSK inhibition was shown to block cell proliferation and protein synthesis in BRAF/MEK inhibitor-resistant melanomas, establishing this pathway as a viable therapeutic strategy against chemoresistance12. Here, RPS6KA2 is linked to melanoma.